Trial Profile
Phase I/II trial of IMO-2125 in combination with ipilimumab and nivolumab in patients with multiple tumor types including non-small cell lung cancer, melanoma, squamous cell carcinoma of the head and neck and urothelial carcinoma.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Tilsotolimod (Primary)
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen
- 06 Nov 2018 According to the Idera Pharmaceuticals media release, The principal investigator initiating this trial is Aurelien Marabelle, MD, PhD, Clinical Director of the Cancer Immunotherapy Program at Institut Gustave Roussy, Villejuif, France.
- 23 Apr 2018 New trial record